Group approach may increase accessibility to psychedelic therapy

This is a report from the Australian National University on their research exploring psychedelic group work: "Evidence continues to build for the use of psychedelic agents, such as psilocybin and MDMA, to treat depression, anxiety, trauma and OCD.  To date, research has focussed on undertaking psychedelic treatment in a one-to-one setting with the patient supported through the therapeutic process by a trained clinician.  Each therapy session takes six or more hours – until the medication wears off.  Given the time commitment for both the patient and clinician, this one-to-one therapeutic approach can create cost barriers to accessing treatment.  In a bid to increase accessibility, a new study by the Australian National University (ANU) School of Medicine and Psychology will look into the viability of the application of psychedelics in a group setting.  The study will focus on the psychological, cognitive and physical effects, including adverse events, of taking psilocybin and MDMA in a group setting."

For more psychedelic news and research, visit the psychedelic health professional network homepage.